Oncimmune Holdings plc
ONC.L · LSE
8/31/2024 | 8/31/2023 | 5/31/2022 | 5/31/2021 | |
|---|---|---|---|---|
| Revenue | £3 | £1 | £4 | £4 |
| % Growth | 137.8% | -70.1% | 3.7% | – |
| Cost of Goods Sold | £2 | £0 | £2 | £1 |
| Gross Profit | £1 | £1 | £1 | £3 |
| % Margin | 44.9% | 68.8% | 37.8% | 76.8% |
| R&D Expenses | £0 | £1 | £2 | £2 |
| G&A Expenses | £2 | £0 | £7 | £6 |
| SG&A Expenses | £2 | £4 | £7 | £6 |
| Sales & Mktg Exp. | £0 | £3 | £0 | £0 |
| Other Operating Expenses | £3 | £0 | £1 | £1 |
| Operating Expenses | £4 | £5 | £10 | £8 |
| Operating Income | -£3 | -£4 | -£9 | -£5 |
| % Margin | -117.8% | -368.2% | -222.5% | -138.2% |
| Other Income/Exp. Net | -£1 | -£2 | -£1 | -£1 |
| Pre-Tax Income | -£4 | -£6 | -£10 | -£6 |
| Tax Expense | -£0 | £0 | -£0 | -£1 |
| Net Income | -£4 | £4 | -£10 | -£5 |
| % Margin | -132.5% | 356.3% | -246.5% | -124.3% |
| EPS | -0.049 | 0.057 | -0.15 | -0.072 |
| % Growth | -186.4% | 137.7% | -109.2% | – |
| EPS Diluted | -0.049 | 0.057 | -0.15 | -0.072 |
| Weighted Avg Shares Out | 74 | 73 | 65 | 65 |
| Weighted Avg Shares Out Dil | 74 | 73 | 65 | 65 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £1 | £2 | £1 | £1 |
| Depreciation & Amortization | £0 | £1 | £0 | £1 |
| EBITDA | -£3 | -£4 | -£8 | -£4 |
| % Margin | -109.6% | -384.6% | -217.4% | -107.5% |